HeartFlow reported a strong Q2 with 48% sales growth and gross margins increasing to 83%, boosting market confidence. The company raised its full-year revenue forecast to $246–$250 million, though this guidance seems conservative given recent momentum and sequential growth. Shares trade at 13 times sales, supported by expanding revenue from plaque-related products and growing adoption of its non-invasive cardiac technology. Despite ongoing operating losses, HeartFlow's solid cash position and large market opportunity suggest potential for further gains, though current valuation limits immediate excitement.
Over the past decade, an investment of $10,000 in AMD grew to more than $700,000, significantly outperforming the S&P 500, which turned the same amount into about $42,000. This highlights AMD's exceptional growth and strong market performance compare...
Swiss Re reported robust first-half 2026 results, achieving a net income of $2.83 billion driven by disciplined underwriting and cost-cutting measures. Its property & casualty segment maintained a combined ratio below 77%, supporting the company's go...
SafePal, a crypto wallet provider, disclosed a data breach affecting nearly 40,000 customers, exposing order-related information such as purchase details and contact info. The breach did not compromise private keys, seed phrases, or wallet balances, ...
Gold prices surpassed $4,400 an ounce, pushing the VanEck Gold Miners ETF (GDX) to levels not seen in over ten years, rising nearly 18% in the past month. This surge is driven by strong free cash flows from major producers like Newmont and Agnico Eag...
Five popular income-focused ETFs—JEPI, JEPQ, QYLD, SPYI, and PFFA—offer different approaches to generating high yields. JEPI and JEPQ use covered-call strategies on large-cap and Nasdaq stocks, respectively, with JEPQ offering higher yields but more ...
